Mark Scott, MD
Critical Care Medicine · Cincinnati, OHNPI 1346290889
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by GSK at 30.0% of the total. Reporting peaked in 2022 at $420 and has fallen 94.5% since, to $23 in 2025.
Across 78 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$375
- Sanofi$120
- Takeda Pharmaceuticals U.S.A., Inc.$92
- Boehringer Ingelheim$90
- Genentech USA, Inc.$86
- AstraZeneca$83
- plus $404 from 13 others
What the payments were for
- Food & beverage$1,249100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 32 | $375 |
| Sanofi | 5 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $92 |
| Boehringer Ingelheim | 5 | $90 |
| Genentech USA, Inc. | 5 | $86 |
| AstraZeneca | 6 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $77 |
| Grifols USA, LLC | 4 | $70 |
| Pulmonx Corporation | 2 | $47 |
| Inogen, Inc. | 2 | $34 |
| Electromed, Inc. | 3 | $33 |
| Mayne Pharma Commercial LLC | 1 | $24 |
| Medtronic | 1 | $23 |
| Advanced Respiratory, Inc | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| Haemonetics Corporation | 1 | $17 |
| Mylan Specialty L.p. | 1 | $17 |
| Philips North America LLC | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$1,249 in reported general payments places this provider in the 80th percentile of 285 critical care medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 36 | $139,871 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $68,428 |
| NucyntaTapentadol Hcl | 13 | $36,457 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $27,346 |
| Spiriva RespimatTiotropium Bromide | 44 | $26,616 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $21,798 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $13,752 |
| EliquisApixaban | 17 | $10,992 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,957 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $7,194 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 253 | $7,123 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $6,840 |
| Theophylline ErTheophylline Anhydrous | 62 | $6,125 |
| AirsupraAlbuterol Sulfate/Budesonide | 13 | $6,091 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 39 | $5,206 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $375 | $110,988169 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Airsupra | $83 | $54,029116 claims |
| Boehringer IngelheimSpiriva Respimat | $90 | $26,61644 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 285 critical care medicine providers in Ohio.
Other critical care medicine in Cincinnati
- Sadia BenzaquenCincinnati$15K
- Maria IndiharCincinnati$8K
- Geoffrey LohCincinnati$7K
- Kiranmayee LankaCincinnati$6K
- Thomas PrestonCincinnati$5K
- Muhammad KhawarCincinnati$5K
- Christopher OrabellaCincinnati$5K
- Adam ColeCincinnati$4K
- Christopher SchmittCincinnati$4K
- Eric WeinsteinCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.